期刊文献+

乳腺癌的靶向治疗药物研究进展 被引量:6

下载PDF
导出
摘要 近年来乳腺癌的发病率一直呈上升趋势,据我国癌症中心2014年公布的数据显示,乳腺癌发病合计为42.55/10万,高居女性恶性肿瘤的第1位。尽管乳腺癌发病率逐年升高,但是其病死率却在下降。这其中最重要的原因就是靶向治疗研究的不断深入,使乳腺癌复发率降低,生存期延长。如赫赛汀,一经上市就给HER-2阳性的患者带来了较高的生存收益[1-2]。
作者 彭芳
出处 《现代中西医结合杂志》 CAS 2016年第14期1586-1588,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
基金 广西自然科学基金项目(2010GXNSFA013132) 北海市科技开发与研究项目(北科合201308002 北科合201203065)
  • 相关文献

参考文献24

  • 1Goldhirsch A,Piccart-Gebhart M,Procter M,et al.HERA TRIAL:2years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow-up[J].Cancer Research,2012(72):2-5.
  • 2Slamon D,Eiermann W,Robert N,et al.Adjuvant trastuzumab in HER2positive breast cancer[J].N Engl J Med,2011(365):1273-1283.
  • 3Citri A,Yarden Y.EGF-ERBB signalling:Towards the systems level[J].Nat Rev Mol Cell Biol,2006,(7):505-516.
  • 4Gazdar AF,Minna JD.Deregulated EGFR signaling during lung cancer progression:Mutations,amplicons,and autocrine loops[J].Cancer Prev Res(Phila),2008(1):156-160.
  • 5Sharma SV,Settleman J.Oncogenic shock:Turning an activated kinase against the tumor cell[J].Cell Cycle,2006(5):2878-2880.
  • 6Au HJ,Eiermann W,Robert NJ,et al.Health-related quelity of life with adjuvant docetaxel-and trastuzumab-based regimens in patients with node-positive and high-risk node-negative,HER2-positive early breast cancer:results from the BCIRG 006 Study[J].Oncologist,2013,18(7):812-818.
  • 7Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastuzumab after adjuvant hemotherapy in HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1659-1672.
  • 8De Luca A,Gallo M,Aldinucci D,et al.The role of the EGFR?ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells[J].J Cell Physiol,2014,12(11):6-18.
  • 9Nahta R,Yu D,Hung MC,et al.Mechanisms of disease:understanding resistance to HER2-targeted therapy in human breast cancer[J].Nat Clin Pract Oncol,2006,3(5):269-280.
  • 10Baselga J,Gelmon KA,Verma S,et al.PhaseⅡtrial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J].J Clin Oncol,2010,28(7):1138-1144.

二级参考文献7

共引文献3

同被引文献66

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部